# A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

> **NCT05234606** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Silverback Therapeutics**

## Conditions studied

- Urothelial Carcinoma
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Hormone Receptor-positive/HER2-negative Breast Cancer

## Interventions

- **DRUG:** SBT6290
- **DRUG:** SBT6290
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT05234606
- **Lead sponsor:** Silverback Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision based on strategic re-alignment
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05234606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05234606, "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05234606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*